Dulaglutide for Weight Loss
Research, mechanism, dosing, and effectiveness of Dulaglutide for weight loss.
Quick Answer
Dulaglutide produces moderate weight loss, though less than semaglutide.
Evidence Level
FDA Approved
Typical Dose
1.5-4.5 mg weekly
Results Timeline
Weight loss over 3-6 months
FDA Status
FDA Approved
How Dulaglutide Works for Weight Loss
GLP-1 reduces appetite and slows gastric emptying.
About Weight Loss
Reduction of body fat and overall body weight through appetite control and metabolic enhancement.
Research Evidence
AWARD program showed significant A1C reduction and weight loss. REWIND trial demonstrated cardiovascular benefits in broader diabetic population. Generally shows 3-5% weight loss in trials.
Dosing for Weight Loss
Recommended Dose
1.5-4.5 mg weekly
Frequency
Once weekly
Administration
Subcutaneous injection weekly
Duration
Long-term / chronic use
Note: FDA-approved as Trulicity. Titrate from 0.75 mg. Convenient once-weekly dosing.
What to Expect
Initial adjustment period. Some users may notice subtle changes.
Early benefits often become noticeable. Continue consistent use.
Most users report meaningful improvements by this point.
Full effects typically realized. Reassess and adjust as needed.
Possible Side Effects
Not everyone experiences these. Individual responses vary.
- •Nausea
- •Diarrhea
- •Vomiting
- •Abdominal pain
- •Injection site reactions
- •Hypoglycemia (with insulin/sulfonylureas)
Frequently Asked Questions
Does Dulaglutide help with weight loss?
Dulaglutide produces moderate weight loss, though less than semaglutide.
How does Dulaglutide work for weight loss?
GLP-1 reduces appetite and slows gastric emptying....
What dose of Dulaglutide should I use for weight loss?
1.5-4.5 mg weekly
How long until I see results?
Weight loss over 3-6 months
Other Peptides for Weight Loss
These peptides are also researched for weight loss.
Semaglutide
FDAA GLP-1 receptor agonist with multiple FDA approvals including weight loss, T2D, CV risk reduction, and kidney protection. Wegovy pill approved Dec 2025 as first oral GLP-1 for weight loss.
Tirzepatide
FDAA dual GIP/GLP-1 receptor agonist representing the next generation of incretin-based therapies. Shows superior weight loss compared to semaglutide in head-to-head trials. First medication approved for obstructive sleep apnea.
Liraglutide
FDAAn FDA-approved GLP-1 receptor agonist for type 2 diabetes and chronic weight management. The predecessor to semaglutide with daily dosing.
Exenatide
FDAThe first GLP-1 receptor agonist approved for diabetes. Derived from Gila monster saliva. Available in twice-daily and weekly formulations.
Educational Information Only
This information about Dulaglutide for weight loss is for educational purposes only. Always consult with qualified healthcare providers before using any peptide. Individual results may vary.